Recent Comments

Comment RSS

Anemia News and Research RSS Feed - Anemia News and Research

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

20. November 2009 08:37
Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis. [More]

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

20. November 2009 05:00
New education strategies for better controlling hypertension and research suggesting a possible link between short-term and long-term exposure to air pollution and increased risk of constricted blood vessels are among the research highlights from studies supported by the National Heart, Lung, and Blood Institute (NHLBI) at the American Heart Association's 2009 Scientific Sessions in Orlando held Nov. 14-18. [More]

Schoolchildren should eat snail pie to reduce malnutrition and iron deficiency, says nutritionist

20. November 2009 02:14
A nutritionist in Nigeria says that malnutrition and iron deficiency in schoolchildren could be reduced in her country by baking up snail pie. In a research paper to be published in the International Journal of Food Safety, Nutrition and Public Health, she explains snail is not only cheaper and more readily available than beef but contains more protein. [More]

Posted in: Medical Condition News

Tags: , , , , , , ,

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

19. November 2009 22:41
Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December. [More]

Posted in: Business / Finance

Tags: , , , , , , , ,

Treatment of iron deficiency can improve symptoms and quality of life in CHF patients

19. November 2009 06:49
Intravenous (I.V.) iron treatment with ferric carboxymaltose to reverse iron deficiency can significantly improve symptoms, exercise tolerance and quality of life for chronic heart failure (CHF) patients, researchers said in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009. [More]

Posted in: Medical Condition News

Tags: , , , ,

Queen’s University Belfast to study individualized radiotherapy treatment for breast cancer

19. November 2009 02:27
Individualised radiotherapy treatment based on a person’s genetic make up could soon become a reality, according to Breast Cancer Campaign. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , ,

New radical approach to test chemo drugs for potential toxic effects

19. November 2009 02:25
Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , ,

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

18. November 2009 10:31
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. [More]

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

18. November 2009 09:14
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. [More]

Phase III randomized clinical trial for Alpharadin to be commenced

18. November 2009 01:30
International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide. [More]

Posted in: Men's Health News | Drug Trial News

Tags: , , , , , , ,

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

17. November 2009 05:02
To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing. [More]

FDA approves Lysteda for treating menorrhagia

16. November 2009 09:04
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , ,

Fully revised and updated text on renal system

16. November 2009 05:55
Research and Markets (http://www.researchandmarkets.com/research/4fdc99/the_renal_system_a) has announced the addition of John Wiley and Sons Ltd's new report "The Renal System at a Glance, 3rd Edition" to their offering. [More]

Lysteda tablets to treat menorrhagia approved by FDA

16. November 2009 00:07
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot. [More]

PillCam capsule endoscopy is useful and safe in children under eight years old: Study

13. November 2009 10:51
Given Imaging Ltd. today announced that a multi-center study published in the November edition of Gut showed PillCam capsule endoscopy of the small bowel to be just as useful and equally as safe in children under eight years old as it is in older children or adults. The prospective multicenter analysis was led by Annette Fritscher-Ravens M.D., Department of Interdisciplinary Endoscopy, University Hospital Kiel, Germany. [More]

Posted in: Child Health News | Device / Technology News

Tags: , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.